MX352481B - Una solución de dipolo magnético estabilizado para tratar o aliviar enfermedades y mejorar el desempeño. - Google Patents
Una solución de dipolo magnético estabilizado para tratar o aliviar enfermedades y mejorar el desempeño.Info
- Publication number
- MX352481B MX352481B MX2013000815A MX2013000815A MX352481B MX 352481 B MX352481 B MX 352481B MX 2013000815 A MX2013000815 A MX 2013000815A MX 2013000815 A MX2013000815 A MX 2013000815A MX 352481 B MX352481 B MX 352481B
- Authority
- MX
- Mexico
- Prior art keywords
- treating
- methods
- magnetic dipole
- enhancing performance
- stabilized solution
- Prior art date
Links
- 230000002708 enhancing effect Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 206010027439 Metal poisoning Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000016709 nutrition Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/12—Magnesium silicate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/40—Peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/20—Halogens; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gerontology & Geriatric Medicine (AREA)
Abstract
La presente invención se refiere a una composición para usarse tratar o aliviar una condición asociada con diabetes, una condición asociada con una disfunción cardiovascular, un cáncer, una infección o un envenenamiento por metal, en donde la composición está adaptada para ser administrable por inyección, en donde dicha composición comprende: una solución de dipolo magnético estabilizado, en donde dicha solución de dipolo magnético estabilizado es un agua electroactivada y que comprende H2O, especies oxidativas estabilizadas que incluyen al menos HOCl, ascorbato de sodio, cloruro de magnesio 2 H2O, HCl de 2-dimetil-amino-etanol, tiamina, riboflavina, nicotinamida, piridoxina, pantotenato de calcio, cianocobalamina y ácido fólico; y uno o más ingredientes seleccionados del grupo que consiste de vitaminas, sales, ácidos, aminoácidos o sales de los mismos, provitaminas, y uno o más de: anestésicos, heparina, y ácido lipoico y sales de los mismos; y en donde dicha composición tienen un potencial eléctrico de -900 a 100 mV.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36685310P | 2010-07-22 | 2010-07-22 | |
US36685210P | 2010-07-22 | 2010-07-22 | |
US36684510P | 2010-07-22 | 2010-07-22 | |
US36684410P | 2010-07-22 | 2010-07-22 | |
PCT/US2011/044947 WO2012012682A2 (en) | 2010-07-22 | 2011-07-22 | Methods of treating or ameliorating diseases and enhancing performance comprising the use of a magnetic dipole stabilized solution |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013000815A MX2013000815A (es) | 2013-06-03 |
MX352481B true MX352481B (es) | 2017-11-27 |
Family
ID=45497473
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013000815A MX352481B (es) | 2010-07-22 | 2011-07-22 | Una solución de dipolo magnético estabilizado para tratar o aliviar enfermedades y mejorar el desempeño. |
Country Status (10)
Country | Link |
---|---|
US (4) | US9572810B2 (es) |
EP (1) | EP2595636A4 (es) |
JP (4) | JP2013532661A (es) |
CN (4) | CN103327986B (es) |
AU (4) | AU2011280985C1 (es) |
BR (1) | BR112013001594A2 (es) |
CA (2) | CA2989896C (es) |
HK (2) | HK1214164A1 (es) |
MX (1) | MX352481B (es) |
WO (1) | WO2012012682A2 (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9101537B2 (en) | 2008-07-25 | 2015-08-11 | Reven Pharmaceuticals, Inc. | Compositions and methods for the prevention and treatment of cardiovascular diseases |
CN103327986B (zh) * | 2010-07-22 | 2018-05-25 | 雷文制药有限公司 | 包含使用磁偶极子稳定化溶液的治疗或改善疾病并增强表现的方法 |
WO2013053076A1 (en) | 2011-10-10 | 2013-04-18 | Zensun (Shanghai)Science & Technology Limited | Compositions and methods for treating heart failure |
CA2914608A1 (en) * | 2013-03-14 | 2014-09-25 | Jsn I, Llc | Taste masking of anesthetics and analgesics |
CN105611955A (zh) | 2013-05-22 | 2016-05-25 | 上海泽生科技开发有限公司 | 缓释纽兰格林治疗心力衰竭 |
US10517892B2 (en) * | 2013-10-22 | 2019-12-31 | Medtronic Minimed, Inc. | Methods and systems for inhibiting foreign-body responses in diabetic patients |
WO2015107375A1 (es) * | 2013-12-20 | 2015-07-23 | Vergara Campillo Ramiro Moises | Combinación de piridoxina, ácido fólico y iones de magnesio para el tratamiento del cáncer |
EP3086785A4 (en) * | 2014-01-01 | 2017-08-30 | Real Time Imaging Technologies, LLC | Improved local anesthetic solution for dental and/or contrast media use |
CN104758922A (zh) | 2014-01-03 | 2015-07-08 | 上海泽生科技开发有限公司 | 纽兰格林制剂的配方 |
CN111407882A (zh) | 2014-10-17 | 2020-07-14 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物 |
US20160317577A1 (en) * | 2015-05-01 | 2016-11-03 | Reoxcyn Discoveries Group, Inc. | Electrolyzed saline redox-balanced compositions and methods for treating skin conditions |
CN106265696A (zh) | 2015-06-12 | 2017-01-04 | 上海泽生科技开发有限公司 | 使用复合维生素b、c组合物促进胃肠系统动力的方法 |
CN105769843A (zh) * | 2016-04-08 | 2016-07-20 | 南京师范大学 | L‐茶氨酸在制备预防或治疗重金属镉引起的机体损伤药物中的应用 |
CN107684561A (zh) * | 2016-08-05 | 2018-02-13 | 上海宣泰生物科技有限公司 | 辅酶q10营养组合物及其应用 |
CN108079008A (zh) | 2016-11-23 | 2018-05-29 | 上海泽生科技开发股份有限公司 | 促进胃肠系统动力的复合维生素组合物 |
CN108567792A (zh) | 2017-03-07 | 2018-09-25 | 上海泽生科技开发股份有限公司 | 一种治疗阿尔茨海默病的复合维生素组合物 |
KR101964841B1 (ko) * | 2017-03-07 | 2019-08-07 | 주식회사 엘지생활건강 | 여성 갱년기 증상 개선용 조성물 |
JP2021505673A (ja) * | 2017-12-07 | 2021-02-18 | リーベン アイピー ホールディングカンパニー リミテッド ライアビリティ カンパニー | 代謝性疾患の治療のための組成物および方法 |
US11364244B2 (en) * | 2018-04-25 | 2022-06-21 | Oncocross Co., Ltd. | Compositions for treatment of muscular disorders |
WO2019240793A1 (en) * | 2018-06-14 | 2019-12-19 | Hewlett-Packard Development Company, L.P. | Access tokens with scope expressions of personal data policies |
CA3111385A1 (en) * | 2018-09-06 | 2020-03-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Sustained-release injectable antibiotical formulation |
CN109350691A (zh) * | 2018-10-12 | 2019-02-19 | 皖西学院 | 一种中药排镉益肾生精膏及其制备方法 |
KR102592426B1 (ko) | 2019-01-02 | 2023-10-23 | 삼성디스플레이 주식회사 | 잉크젯 프린팅 장치, 쌍극자 정렬 방법 및 표시 장치의 제조 방법 |
TW202102664A (zh) * | 2019-03-15 | 2021-01-16 | 日商美加細胞股份有限公司 | 哺乳動物細胞之保存液 |
CA3141418A1 (en) * | 2019-06-12 | 2020-12-17 | James Ervin | Methods and compositions for improving outcomes of cancer patients |
TWI727680B (zh) * | 2020-02-27 | 2021-05-11 | 超水國際股份有限公司 | 次氯酸消毒劑及其生產方法 |
WO2021257009A1 (en) * | 2020-06-08 | 2021-12-23 | Erdogan Fatma Gulru | A drug-free antibacterial lotion |
US20230301953A1 (en) * | 2020-08-10 | 2023-09-28 | Oncocross Co.,Ltd. | Composition for prevention and treatment of myopathy |
IL301794A (en) * | 2020-09-30 | 2023-05-01 | Reven Pharmaceuticals Inc | Pharmaceutical compositions and methods for the prevention and/or treatment of inflammations |
US20220233504A1 (en) * | 2021-01-23 | 2022-07-28 | Cellix Bio Private Limited | Pharmaceutical composition comprising lidocaine and melatonin |
Family Cites Families (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2750159C3 (de) | 1977-11-09 | 1980-05-22 | Lentia Gmbh, Chem. U. Pharm. Erzeugnisse - Industriebedarf, 8000 Muenchen | Infusionslösung zur Behandlung von hepatischer Encephalopathie und ein Verfahren zu deren Herstellung |
US4837342A (en) | 1986-02-28 | 1989-06-06 | Sagami Chemical Research Center | Prostacyclin analogue, and blood circulation improving agent and anti-ulcer composition containing it as active ingredient |
US5080886A (en) | 1990-01-05 | 1992-01-14 | Sterling Drug Inc. | Pharmaceutical compositions for the prevention and treatment of oxidant injuries |
US6544502B2 (en) * | 1992-09-11 | 2003-04-08 | Wasatch Pharmaceutical Inc. | Skin treatment with a water soluble antibiotic dissolved in an electrolyzed water |
JPH0725858A (ja) | 1993-07-13 | 1995-01-27 | Otsuka Pharmaceut Co Ltd | ピペラジン誘導体 |
WO1995028906A1 (fr) * | 1994-04-20 | 1995-11-02 | The Green Cross Corporation | Recipient de perfusion, preparation d'un solute et solute vitamine hautement calorique complet |
JP3193295B2 (ja) * | 1995-07-07 | 2001-07-30 | 株式会社日本トリム | 透析装置 |
JPH0925236A (ja) * | 1995-07-12 | 1997-01-28 | Koichiro Kameyama | 亜鉛含有アルカリ電解水 |
JPH0959150A (ja) | 1995-08-11 | 1997-03-04 | Roussel Morishita Kk | 経静脈用輸液製剤 |
JP3481761B2 (ja) | 1996-01-30 | 2003-12-22 | 忠正 中村 | 電解水の生成方法 |
JPH10272468A (ja) | 1997-03-28 | 1998-10-13 | Toto Ltd | 酸性電解水生成用添加物 |
WO1999010286A1 (fr) | 1997-08-27 | 1999-03-04 | Miz Co., Ltd. | Cellule electrolytique et dispositif de production d'eau electrolysee |
US20040131695A1 (en) | 1997-10-23 | 2004-07-08 | Radical Waters Ip (Pty) Ltd. | Use of an aqueous solution in the treatment of live animals |
ES2217607T3 (es) | 1997-12-04 | 2004-11-01 | Steris Corporation | Modificacion quimica de agua activada electroquimicamente. |
JPH11209307A (ja) | 1998-01-19 | 1999-08-03 | Sankyo Co Ltd | 脂溶性薬物含有注射用製剤 |
US20030089618A1 (en) | 1998-04-10 | 2003-05-15 | Miz Co., Ltd. | Reducing electrolyzed water and method for producing same |
RU2142917C1 (ru) | 1998-06-30 | 1999-12-20 | Попов Алексей Юрьевич | Способ и устройство для электрохимической обработки воды |
JP2000033377A (ja) | 1998-07-22 | 2000-02-02 | Mizu Kk | 還元性電解水 |
US6284786B1 (en) * | 1999-02-16 | 2001-09-04 | The Center For The Improvement Of Human Functioning, Int'l., Inc. | Treatment of cancer using lipoic acid in combination with ascorbic acid |
US7052600B2 (en) | 1999-03-05 | 2006-05-30 | Enproamerica, Inc. | Apparatus for treating water |
US6312663B1 (en) * | 1999-03-19 | 2001-11-06 | Joseph V. Boykin, Jr. | Prediction of diabetes impaired wound healing by urinary nitrate assay |
EP1176938A4 (en) | 1999-04-29 | 2004-04-07 | Henceforth Hibernia Inc | AQUEOUS BIOMIMETIC SOLUTIONS AND COMPOSITIONS, THEIR USE AS CARE AND BEAUTY PRODUCTS AND CONSTITUENTS THEREOF, AND THEIR PREPARATION METHODS |
JP2003500193A (ja) | 1999-05-24 | 2003-01-07 | シーツ,リチャード,ジー. | 閉鎖環境における浄化・修復水による物質の再生 |
US20050037065A1 (en) * | 1999-05-27 | 2005-02-17 | Drugtech Corporation | Nutritional formulations |
WO2000076556A2 (en) | 1999-06-11 | 2000-12-21 | Neorx Corporation | High dose radionuclide complexes for bone marrow suppression |
US6649193B1 (en) | 1999-06-11 | 2003-11-18 | Henceforth Hibernia Inc. | Prophylactic therapeutic and industrial antioxidant compositions enhanced with stabilized atomic hydrogen/free electrons and methods to prepare and use such compositions |
US20040110684A1 (en) | 1999-08-02 | 2004-06-10 | Universite Catholique De Louvain | Novel pharmaceutical compositions for modulating angiogenesis |
WO2001019365A1 (en) | 1999-09-15 | 2001-03-22 | Roche Consumer Health Ag | Pharmaceutical and/or cosmetical compositions |
JP2001139477A (ja) * | 1999-11-17 | 2001-05-22 | Coherent Technology:Kk | 創傷部位の組織細胞増殖促進液 |
US6426066B1 (en) | 2000-01-12 | 2002-07-30 | California Pacific Labs, Inc. | Use of physiologically balanced, ionized, acidic solution in wound healing |
US7393522B2 (en) | 2000-01-12 | 2008-07-01 | Novabay Pharmaceuticals, Inc. | Physiologically balanced, ionized, acidic solution and methodology for use in wound healing |
WO2001089520A2 (en) | 2000-05-19 | 2001-11-29 | Progenics Pharmaceuticals, Inc. | Dehydroascorbic acid formulations and uses thereof |
JP3602773B2 (ja) | 2000-06-08 | 2004-12-15 | 株式会社ミクニ | 陽極電解水、及びその製造方法 |
US20020023847A1 (en) | 2000-06-23 | 2002-02-28 | Shinichi Natsume | Cleansing system and method using water electrolysis |
CA2313659A1 (en) * | 2000-07-06 | 2002-01-06 | Barry J. Barclay | B complex vitamin compositions that protect against cellular damage caused by ultraviolet light |
US6432425B1 (en) | 2000-09-08 | 2002-08-13 | Al Siamon | Method for treatment with an antibacterial and antiseptic mixture |
ATE327747T1 (de) * | 2000-10-09 | 2006-06-15 | Matthias Dr Med Rath | Therapeutische kombination des ascorbats mit lysin und arginin für verhinderung und behandlung des krebses |
AU2002220960B2 (en) | 2000-12-08 | 2006-12-21 | Pieter Theo Ernst | Regeneration of blood vessels |
CA2442396A1 (en) | 2001-02-28 | 2002-09-12 | Brian C. Giles | Method and formula for anti-tumor and anti-matastatic effect |
EP1238945A1 (en) | 2001-03-07 | 2002-09-11 | Hoshizaki Denki Kabushiki Kaisha | Electrolyzed water production apparatus |
JP2002301476A (ja) | 2001-04-10 | 2002-10-15 | Mikuni Corp | アスコルビルグルコサミン電解生成水、及びその製造方法 |
US6572902B2 (en) | 2001-04-25 | 2003-06-03 | Advanced H2O, Inc. | Process for producing improved alkaline drinking water and the product produced thereby |
JP2002338498A (ja) * | 2001-05-17 | 2002-11-27 | Takeda Chem Ind Ltd | 内服用液剤 |
JP2002336856A (ja) | 2001-05-18 | 2002-11-26 | Mikuni Corp | 電解水製造装置、及び電解水の製造方法 |
JP2002361250A (ja) * | 2001-06-12 | 2002-12-17 | San Waaku:Kk | 活性水素含有水の製法 |
WO2007140544A1 (en) | 2006-06-09 | 2007-12-13 | Gomez Rodolfo Antonio M | Electrolytic activation of water |
US6968382B2 (en) * | 2001-07-12 | 2005-11-22 | International Business Machines Corporation | Activating a volume group without a quorum of disks in the volume group being active |
US20040013768A1 (en) | 2001-08-13 | 2004-01-22 | Khatchatrian Robert G. | Method of obtaining ethyl alcohol or aqueous-alcoholic solution for preparation of vodka |
US6942767B1 (en) | 2001-10-12 | 2005-09-13 | T-Graphic, Llc | Chemical reactor system |
KR100419536B1 (ko) | 2001-11-02 | 2004-02-19 | 강송식 | 전기분해 정수기 |
US20030105104A1 (en) * | 2001-11-27 | 2003-06-05 | Burzynski Stanislaw R. | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy |
WO2003050044A1 (en) | 2001-12-10 | 2003-06-19 | Radical Waters (Ip) (Pty) Limited | Electrochemically activated water for the treatment of cystitis |
KR20030047864A (ko) | 2001-12-11 | 2003-06-18 | 시아오 빙 왕 | 플라크의 산발생에 대한 완충제의 영향 |
JPWO2003064332A1 (ja) | 2002-01-29 | 2005-05-26 | 本田技研工業株式会社 | 水の活性化装置および活性化方法 |
US20050170011A1 (en) | 2002-04-26 | 2005-08-04 | Tomoyuki Yanagihara | Method of inhibiting oxidation, water capable of inhibiting oxidation and use thereof |
JP3788389B2 (ja) | 2002-05-30 | 2006-06-21 | 株式会社デンソー | 水改質装置 |
JP2004008973A (ja) * | 2002-06-07 | 2004-01-15 | Hoshizaki Electric Co Ltd | 電解水の製造方法 |
US6855233B2 (en) | 2002-11-15 | 2005-02-15 | Kinji Sawada | Apparatus for production of strong alkali and acid electrolytic solution |
JP2004175692A (ja) * | 2002-11-25 | 2004-06-24 | Fuso Pharmaceutical Industries Ltd | 抗腫瘍剤 |
US20050175759A1 (en) | 2004-02-09 | 2005-08-11 | Atul Singhal | Newborn infant formulas and feeding methods |
JP2004261656A (ja) | 2003-02-25 | 2004-09-24 | Mikuni Corp | 混合電解水の製造方法 |
US20060263441A1 (en) | 2003-03-04 | 2006-11-23 | Kenji Fukui | Free radical solution water |
US20060191785A1 (en) | 2003-04-30 | 2006-08-31 | Sanden Corporation | Mineral water generator |
WO2005015959A1 (de) | 2003-08-05 | 2005-02-17 | Technische Universität Braunschweig Carolo-Wilhelmina | Verwendung einer schicht aus hydrophoben, linear oder zweidimensional polyzyklischen aromaten als sperrschicht oder kapselung und mit einer derartigen schicht aufgebaute elektrische bauelemente mit organischen polymeren |
US20050029198A1 (en) * | 2003-08-08 | 2005-02-10 | Frederick Tepper | Heavy metals absorbent and method of use |
JP4653945B2 (ja) | 2003-10-24 | 2011-03-16 | ミズ株式会社 | 薬理機能水、およびその用途 |
WO2005044176A2 (en) | 2003-11-10 | 2005-05-19 | Lipogen Ltd. | Compositions containing phosphatidic acid, methods of use thereof, methods of manufacture thereof, and articles of manufacture containing same |
GB0328124D0 (en) | 2003-12-04 | 2004-01-07 | Daly James | Membrane electrolyser with a two part end design |
US20050196462A1 (en) * | 2003-12-30 | 2005-09-08 | Oculus Innovative Sciences, Inc. | Topical formulation containing oxidative reductive potential water solution and method for using same |
US20050139808A1 (en) | 2003-12-30 | 2005-06-30 | Oculus Innovative Sciences, Inc. | Oxidative reductive potential water solution and process for producing same |
US20050209170A1 (en) * | 2004-03-18 | 2005-09-22 | Takemoto Arnold C | Breast health preparations |
US20060008908A1 (en) * | 2004-07-08 | 2006-01-12 | Giles Brian C | Method and composition for longevity assurance |
JP2006068617A (ja) | 2004-09-01 | 2006-03-16 | Ebara Corp | 水媒体の処理方法及び装置 |
WO2006035523A1 (ja) | 2004-09-27 | 2006-04-06 | Hoshizaki Denki Kabushiki Kaisha | 免疫賦活剤、その生成方法および生成装置 |
US8916050B2 (en) * | 2004-09-27 | 2014-12-23 | Special Water Patents B.V. | Methods and compositions for treatment of water |
JP2006098003A (ja) | 2004-09-30 | 2006-04-13 | Kurita Water Ind Ltd | 循環型冷却水系の電解処理方法及び電解処理装置 |
JP2006104147A (ja) * | 2004-10-07 | 2006-04-20 | Otsuka Pharmaceut Factory Inc | 経口・経腸栄養組成物 |
US8062501B2 (en) * | 2004-10-08 | 2011-11-22 | Ube Industries, Ltd. | Neutral electrolytic water, neutral electrolytic water production method and device thereof |
WO2006055526A2 (en) * | 2004-11-16 | 2006-05-26 | Nu-Tein Co., Inc. | Compositions useful to treat ocular neovascular diseases and macular degeneration |
JP2006255613A (ja) | 2005-03-17 | 2006-09-28 | Seiki Shiga | 活性水素溶存水の生成方法、生成器および生成用の石こう供給部材、並びに活性水素の生成性物質とその製造方法 |
KR101532778B1 (ko) * | 2005-03-23 | 2015-06-30 | 오클루스 이노바티브 사이언시즈 인코포레이티드 | 산화 환원 전위 수용액을 사용한 2도 및 3도 화상의 치료방법 |
WO2006107760A1 (en) * | 2005-04-01 | 2006-10-12 | Electric Aquagenics Unlimited | Electrolyzed water treatment for poultry products |
EP1721868A1 (en) | 2005-05-13 | 2006-11-15 | Osg Corporation Co., Ltd. | Additive solution for use in the production of electrolyzed hypochlorous acid-containing sterilizing water |
US20060275387A1 (en) * | 2005-06-03 | 2006-12-07 | BAGLEY David | Processed water and therapeutic uses thereof |
JP4410155B2 (ja) | 2005-06-16 | 2010-02-03 | ペルメレック電極株式会社 | 電解水噴出装置 |
JP2007000750A (ja) * | 2005-06-23 | 2007-01-11 | Spring:Kk | 活性酸素消去剤、及び活性酸素消去剤の製造方法 |
CU23432B6 (es) | 2005-11-02 | 2009-10-16 | Ct Ingenieria Genetica Biotech | Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras |
WO2007072147A2 (en) | 2005-12-19 | 2007-06-28 | Ernst, Johanna, Catarina | Composition for diagnosing and treating circulatory system diseases |
US20070196357A1 (en) * | 2006-01-20 | 2007-08-23 | Oculus Innovative Sciences, Inc. | Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution |
CA2579517A1 (en) | 2006-02-24 | 2007-08-24 | Kimihiro Sato | Ionized water and method of producing same |
JP2007253131A (ja) * | 2006-03-27 | 2007-10-04 | Takaoka Kasei Kogyo Kk | 抗酸化剤を含有する機能水 |
US7374645B2 (en) | 2006-05-25 | 2008-05-20 | Clenox, L.L.C. | Electrolysis cell assembly |
JP4653708B2 (ja) | 2006-08-28 | 2011-03-16 | 本田技研工業株式会社 | 電解水の生成方法及びそれに用いる電解水生成装置 |
GB2442519A (en) | 2006-10-02 | 2008-04-09 | Forum Bioscience Holdings Ltd | Wound treatment compositions |
GEP20115337B (en) | 2007-01-10 | 2011-11-25 | St Di Ricerche Di Biologia Molecolare P Angeletti Spa | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors |
JPWO2009008318A1 (ja) * | 2007-07-10 | 2010-09-09 | 公立大学法人県立広島大学 | 電解還元水及び入浴用温水及び脂肪塊の抑制方法 |
US20130243883A1 (en) | 2007-10-30 | 2013-09-19 | Reoxcyn Discoveries Group, Inc. | Stable formulations |
US20140050800A1 (en) | 2007-10-30 | 2014-02-20 | Reoxcyn Discoveries Group, Inc. | Method of reducing oxidative stress |
US9486481B2 (en) | 2007-10-30 | 2016-11-08 | Reoxcyn Discoveries Group, Inc. | Method of modulating fatty acid mobilization and oxidation |
US8367120B1 (en) | 2007-10-31 | 2013-02-05 | Reoxcyn Discoveries Group, Inc. | Method and apparatus for producing a stablized antimicrobial non-toxic electrolyzed saline solution exhibiting potential as a therapeutic |
US9446072B2 (en) | 2007-10-30 | 2016-09-20 | Reoxcyn Discoveries Group, Inc. | Methods of ameliorating oxidative stress by increasing the efficiency of GPX and SOD activity |
US8455010B1 (en) | 2007-10-31 | 2013-06-04 | Reoxcyn Discoveries Group, Inc | Product and method for producing an immune system supplement and performance enhancer |
US20150093451A1 (en) | 2007-10-30 | 2015-04-02 | Reoxcyn Discoveries Group, Inc. | Method of increasing energy expenditure |
US20140044800A1 (en) | 2007-10-30 | 2014-02-13 | Daniel Robinson | Stable Reactive Oxygen Composition |
JP4524715B2 (ja) * | 2008-07-14 | 2010-08-18 | 広島化成株式会社 | ミネラル含有加水素水およびその製造方法 |
US9101537B2 (en) | 2008-07-25 | 2015-08-11 | Reven Pharmaceuticals, Inc. | Compositions and methods for the prevention and treatment of cardiovascular diseases |
CN101717160A (zh) * | 2009-05-11 | 2010-06-02 | 杨思博 | 负电位酸性水及其制取方法 |
AU2010260446B2 (en) * | 2009-06-16 | 2015-10-08 | Dusan Miljkovic | Compositions and methods for producing stable negative oxidation reduction potential in consumable materials |
WO2011085316A2 (en) | 2010-01-08 | 2011-07-14 | Clenox Management Llc | System and method for preparation of antimicrobial solutions |
CN103327986B (zh) * | 2010-07-22 | 2018-05-25 | 雷文制药有限公司 | 包含使用磁偶极子稳定化溶液的治疗或改善疾病并增强表现的方法 |
WO2015107731A1 (ja) | 2014-01-14 | 2015-07-23 | 株式会社マキタ | 作業機 |
-
2011
- 2011-07-22 CN CN201180041533.9A patent/CN103327986B/zh not_active Expired - Fee Related
- 2011-07-22 MX MX2013000815A patent/MX352481B/es active IP Right Grant
- 2011-07-22 EP EP11810437.1A patent/EP2595636A4/en not_active Withdrawn
- 2011-07-22 CA CA2989896A patent/CA2989896C/en not_active Expired - Fee Related
- 2011-07-22 CN CN201510487286.5A patent/CN104997803B/zh not_active Expired - Fee Related
- 2011-07-22 CN CN201810372054.9A patent/CN108420827A/zh active Pending
- 2011-07-22 JP JP2013520876A patent/JP2013532661A/ja active Pending
- 2011-07-22 WO PCT/US2011/044947 patent/WO2012012682A2/en active Application Filing
- 2011-07-22 CN CN201710950843.1A patent/CN107670044A/zh active Pending
- 2011-07-22 AU AU2011280985A patent/AU2011280985C1/en not_active Ceased
- 2011-07-22 BR BR112013001594A patent/BR112013001594A2/pt not_active Application Discontinuation
- 2011-07-22 CA CA2806208A patent/CA2806208C/en not_active Expired - Fee Related
-
2013
- 2013-09-04 US US14/017,811 patent/US9572810B2/en active Active
-
2016
- 2016-01-07 AU AU2016200103A patent/AU2016200103A1/en not_active Abandoned
- 2016-02-26 HK HK16102291.4A patent/HK1214164A1/zh unknown
- 2016-09-28 JP JP2016189741A patent/JP6348942B2/ja not_active Expired - Fee Related
-
2017
- 2017-01-04 US US15/398,233 patent/US9867849B2/en active Active
- 2017-12-20 US US15/848,853 patent/US11202798B2/en active Active
-
2018
- 2018-06-01 JP JP2018105762A patent/JP2018131469A/ja not_active Withdrawn
- 2018-07-24 HK HK18109579.0A patent/HK1250141A1/zh unknown
-
2019
- 2019-05-31 AU AU2019203820A patent/AU2019203820B2/en not_active Ceased
-
2020
- 2020-07-17 JP JP2020122810A patent/JP2020169220A/ja active Pending
- 2020-12-07 AU AU2020286177A patent/AU2020286177A1/en not_active Abandoned
-
2021
- 2021-11-24 US US17/534,667 patent/US20220079978A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX352481B (es) | Una solución de dipolo magnético estabilizado para tratar o aliviar enfermedades y mejorar el desempeño. | |
WO2013122932A3 (en) | Topical use of a skin-commensal prebiotic agent and compositions containing the same | |
WO2015009726A3 (en) | Medical uses of cd38 agonists | |
PH12014501639A1 (en) | Pharmaceutical compositions and methods | |
MX2019000225A (es) | Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades. | |
NZ702053A (en) | Anti-human trop-2 antibody having antitumor activity in vivo | |
WO2012006421A3 (en) | Diagnosis and treatment of breast cancer | |
MY162146A (en) | Pharmaceutical composition | |
MX2019006379A (es) | Induccion de gen de trail de molecula pequeña en celulas normales y tumorales como una terapia anticancer. | |
MX2011007397A (es) | Inhibidores de dpp-iv para el tratamiento de la diabetes en pacientes pediatricos. | |
FR2969495B1 (fr) | Extrait de parties aeriennes de maca riche en polyphenols et composition le comprenant | |
MX353964B (es) | Agentes terapeuticos y usos de los mismos. | |
WO2012170776A3 (en) | Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy | |
MX2012013875A (es) | Anticuerpos de union sparc en sangre periferica y usos de los mismos. | |
MD4112B1 (en) | Coordinative compounds of copper with 4-(dimethylphenyl)-thiosemicarbazones of 2-formylpyridine | |
AU2011208681A8 (en) | Aqueous solution comprising 3 - quinuclidinones for the treatment of hyperproliferative, autoimmune and heart disease | |
MX2010006650A (es) | Materiales y metodos para el tratamiento de proliferacion vascular ocular patologica. | |
WO2008060945A3 (en) | Diagnosis and treatment of breast cancer | |
EA201490800A1 (ru) | Способ ингибирования деубиквитинирующей активности | |
MX342947B (es) | Tratamiento de diabetes tipo 2. | |
NZ613085A (en) | Thiosemicarbazone compounds and use in the treatment of cancer | |
WO2012116990A3 (en) | Novel use | |
MX2014010940A (es) | El uso de antitrombina en el tratamiento de preeclampsia. | |
MX2013006319A (es) | Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek. | |
IN2014KN02914A (es) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |